The Manufacturers Life Insurance Company Reduces Position in Immatics (NASDAQ:IMTX)

The Manufacturers Life Insurance Company trimmed its position in Immatics (NASDAQ:IMTX - Free Report) by 43.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,279 shares of the company's stock after selling 71,487 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.08% of Immatics worth $663,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Virtus ETF Advisers LLC grew its position in Immatics by 34.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after acquiring an additional 2,479 shares in the last quarter. Guggenheim Capital LLC purchased a new position in Immatics in the fourth quarter worth about $101,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Immatics by 24.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company's stock worth $163,000 after acquiring an additional 4,477 shares in the last quarter. Aristides Capital LLC purchased a new position in Immatics in the fourth quarter worth about $205,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Immatics in the fourth quarter worth about $211,000. 64.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st.

Immatics Price Performance

Shares of NASDAQ:IMTX opened at $5.12 on Thursday. Immatics has a 1 year low of $3.30 and a 1 year high of $13.77. The business has a 50 day simple moving average of $4.52 and a two-hundred day simple moving average of $5.78. The firm has a market capitalization of $622.34 million, a PE ratio of -7.76 and a beta of 0.87.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The business had revenue of $20.12 million during the quarter, compared to analyst estimates of $14.92 million. Equities research analysts expect that Immatics will post -0.72 EPS for the current fiscal year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.